.jpg)
1 hour ago
2
Article content
- National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie’s commitment to a thriving biotech ecosystem in Quebec.
- Award provides RIME Therapeutics with a year of laboratory and office space, including access to shared equipment and services at the adMare Innovation Centre in Montreal, as well as mentorship from AbbVie’s scientific and business leaders.
- RIME Therapeutics to impact inflammation and immunology research and innovation.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
MONTREAL, April 30, 2026 (GLOBE NEWSWIRE) — AbbVie (NYSE: ABBV), jointly with adMare BioInnovations, today recognized RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award, a prize designed to help foster innovation and support growth in Quebec’s life sciences sector.
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Founded in 2025, RIME Therapeutics is a Montreal-based start-up focused on developing a peptide-based drug discovery platform designed to identify protein-protein interaction targets and accelerate the discovery of therapies for inflammation and immunology. The company impressed the selection committee with its function-first disruptive approach, merging target discovery with simultaneous hit identification, and designed to address novel T cell biology with broad therapeutic applicability.
Article content
An environment that values innovation is essential to foster growth in Canada’s life sciences sector. Enabling partnerships and offering the right infrastructure, mentorship and collaboration to support early-stage biotech entrepreneurs play a critical role in advancing the next generation of breakthrough therapies for people living with devastating diseases in Canada.
Article content
Article content
The AbbVie Biotech Innovators Award supports early-stage biotechnology companies with the potential to generate transformational therapies in areas that align with AbbVie’s therapeutic areas of focus, including immunology, oncology, neuroscience, and aesthetics. Funded by AbbVie, the award will provide RIME Therapeutics with one year of laboratory and office space at the adMare Innovation Centre in Montreal, including access to shared equipment and services. The company will also benefit from the expertise and mentorship of AbbVie’s scientific and business leaders to help accelerate the advancement of its research.
Article content
“We are honoured to receive the AbbVie Biotech Innovators Award to further support our work at RIME,” said Michael Mee, CEO at RIME Therapeutics and Managing Director of Pre-Amp, Amplitude Ventures’ company creation studio. “Our Disruptide Platform is built to solve one of drug discovery’s most persistent challenges, bridging the gap between knowing what to drug and knowing how to drug it. With the support of AbbVie and adMare BioInnovations, we are accelerating our path from novel biology to tractable chemistry, moving towards a differentiated pipeline of medicines for patients.”
English (US)